Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Myeloproliferative Disorders 1

Interventions

Cyclophosphamide 229 fludarabine phosphate 206 fludarabine 163 Busulfan 150 Mycophenolic Acid 135 Tacrolimus 133 Whole-Body Irradiation 132 Peripheral Blood Stem Cell Transplantation 121 Cytarabine 101 Azacitidine 100 Antilymphocyte Serum 98 Melphalan 96 Cyclosporine 96 Methotrexate 87 Imatinib Mesylate 87 Filgrastim 85 Decitabine 66 Granulocyte Colony-Stimulating Factor 60 Thiotepa 57 venetoclax 53 Stem Cell Transplantation 53 thymoglobulin 51 Radiotherapy 49 Cord Blood Stem Cell Transplantation 42 nilotinib 40 Clofarabine 38 Dasatinib 37 Methylprednisolone 36 ruxolitinib 35 Etoposide 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Hydroxyzine × Myeloid × Clear all

NCT03808805 2025-12-03

APHYPAP

University Hospital, Brest

Phase 3 Completed

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡